When research firm IDC put out its latest numbers on global tablet sales, it noted that "[o]ne in every two tablets shipped this quarter was below 8 inches in screen size." The firm believes that the shift to smaller devices will accelerate, making it little surprise that, according to The Wall Street Journal, Microsoft (NASDAQ: MSFT ) is developing a 7-inch Surface tablet to be released sometime this year. IDC expects Google's (NASDAQ: GOOG ) Android operating system to snatch the top market share position from Apple's (NASDAQ: AAPL ) iOS. At this size, Microsoft is competing with the Google Nexus 7, the iPad Mini, and Amazon.com's (NASDAQ: AMZN ) Kindle Fire HD. While this is stiff competition, getting in the fight is a critical step for Microsoft.
The tablet market
Not that there's any doubt as to how important the tablet market is, but the numbers are compelling. IDC raised its forecast for worldwide tablet shipments from 172.4 million units in 2013 to 190.9 million and expects that by 2017, 350 million units will be shipping each year. Apple and Google may rule the sandbox, but it's a big enough sandbox that carving out even a small corner can mean real and meaningful revenue for Microsoft. IDC expects that Microsoft, between its Windows OS and RT OS, account for a combined 10.1% by 2017. These projections don't include a smaller Surface, so the addition could prove to be meaningful.
Best Prefered Companies To Own For 2015: Hansen Medical Inc.(HNSN)
Hansen Medical, Inc. develops, manufactures, and sells medical robotics designed for positioning, manipulation, and control of catheters and catheter-based technologies. The company?s products comprise the Sensei Robotic Catheter System and its related Artisan and Lynx catheters. It offers Sensei Robotic Catheter systems and Artisan catheters for manipulation, positioning, and control of mapping catheters during electrophysiology procedures. The company also provides robotic platforms consisting of the Magellan Robotic System and the NorthStar Robotic Catheter for the treatment of vascular disease. In addition, it offers CoHesion 3D Visualization Module, a software interface that provide physicians with 3D visualization to augment their ability to move a catheter throughout the heart, as well as control the placement of the catheter in specific locations. The company sells its products through direct sales force in the United States; and through direct sales force and dis tributors primarily in the European Union and internationally. It has a joint development agreement and co-marketing agreement with St. Jude Medical, Inc. for the development of CoHesion 3D Visualization Module; and a collaboration agreement with Philips Medical Systems Nederland B.V. to co-develop integrated products for use in the diagnosing and treatment of arrhythmias. The company was founded in 2002 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap medical robotics stock MAKO Surgical Corp (NASDAQ: MAKO) soared 82.19% after it was announced that Stryker Corporation (NYSE: SYK) would acquire it���meaning it might be time to take a closer look at large cap medical robotics leader Intuitive Surgical, Inc (NASDAQ: ISRG) along with small caps Accuray Incorporated (NASDAQ: ARAY) and Hansen Medical, Inc (NASDAQ: HNSN). MAKO Surgical Corp�markets both its RIO Robotic Arm Interactive Orthopedic System and proprietary RESTORIS family of implants to surgeons for a procedure called MAKOplastythat provides a less invasive method for knee resurfacing and a new procedure for Total Hip Arthroplasty.�Stryker Corporation, whose medical technologies include reconstructive, medical and surgical, and neurotechnology and spine products, agreed to pay $1.65 billion or $30 a share for a massive 86%�premium for MAKO Surgical Corp. That�� sounds great for investors unless you are an investor who go in the stock back in 2011 and early 2012 when shares hit as high as the�$43 level.
5 Best Shipping Stocks To Own For 2014: Furiex Pharmaceuticals Inc (FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.
Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.
The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014. - [By CRWE]
Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) reported dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
- [By John Udovich]
Yesterday, small cap drug development collaboration company Furiex Pharmaceuticals Inc (NASDAQ: FURX) surged 129.91% after announcing that its experimental drug had alleviated diarrhea and abdominal pain caused by irritable bowel syndrome in two studies, meaning its worth taking a closer look at the stock because that�� a condition that effects millions of people (with no other effective drug to treat it) plus take a look at the�performance of biotech benchmarks iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Forest Laboratories Inc.(FRX) agreed to acquire Furiex Pharmaceuticals(FURX) in a deal worth up to $1.33 billion that expands Forest Labs’ presence in gastroenterology. Furiex surged 28% to $102.21 premarket.
5 Best Shipping Stocks To Own For 2014: Aixtron SE (AIXG)
AIXTRON SE (AIXTRON), formerly AIXTRON AG, incorporated in 1983, is a provider of deposition equipment equipment to the semiconductor and compound-semiconductor industry. The Company's technology solutions are used by a diverse range of customers worldwide to build advanced components for electronic and opto-electronic applications based on compound, silicon, or organic semiconductor materials. Such components are used in fiber optic communication systems, wireless and mobile telephony applications, optical and electronic storage devices, computing, signaling and lighting, displays, as well as a range of other technologies. AIXTRON's business activities include developing, producing and installing equipment for coating semiconductor materials, process engineering, consulting and training, including ongoing customer support. AIXTRON supplies to customers both full production-scale complex material deposition systems and small scale systems for research and development (R&D) use and small-scale production use.
AIXTRON's product range includes customized production and research scale compound semiconductor systems capable of depositing material films on up to 95 * two-inch diameter wafers per single production run, or smaller multiples of larger diameter wafers, employing MOCVD or Hydride Vapor Phase Epitaxy (HVPE) or organic thin film deposition on up to Gen. 3.5 substrates, including Polymer Vapor Phase Deposition (PVPD) or Organic Vapor Phase Deposition (OVPD) or large area deposition for Organic Light Emitting Diodes (OLED) applications or Plasma Enhanced Chemical Vapor Phase Deposition (PECVD) for depositing complex Carbon Nanostructures (Carbon Nanotubes, Nanowires or Graphene). AIXTRON also manufactures full production and research scale deposition systems for silicon semiconductor applications capable of depositing material films on wafers of up to 300 millimeters diameter, employing technologies, such as Chemical Vapor Deposition (CVD), Atomic Vapor Deposition (AVD) and Atomic Layer! Deposition (ALD).
AIXTRON also offers a range of peripheral equipment and services, including products capable of monitoring the concentration of gases in the air and for cleaning the exhaust gas from metal organic chemical vapor deposition processes. The Company also assists its customers in designing the production layouts for the gas supply to thin film deposition systems. Additionally, the Company offers its customers training, consulting and support services.
The Company competes with Veeco Instruments Inc. (USA), Taiyo Nippon Sanso (Japan), Ulvac, Inc. (Japan), Tokki Corporation (Japan), Sumitomo (Japan), Applied Materials, Inc. (USA), Doosan DND Co., Ltd. (South Korea), Sunic System (South Korea), Tokyo Electron Ltd. (Japan), ASM International N.V. (Netherlands), IPS Technology (South Korea), Jusung Engineering Co. Ltd. (South Korea), and Hitachi Kokusai Electric Co. Inc. (Japan).
Advisors' Opinion:- [By Jon C. Ogg]
Aixtron SE (NASDAQ: AIXG) was downgraded to Sell from Hold at Canaccord Genuity.
Buffalo Wild Wings Inc. (NASDAQ: BWLD) was downgraded to Outperform from Strong Buy at Raymond James.
5 Best Shipping Stocks To Own For 2014: Cardtronics Inc.(CATM)
Cardtronics, Inc., together with its subsidiaries, provides automated consumer financial services through its network of automated teller machines (ATMs) and multi-function financial services kiosks. As of December 31, 2011, it offered services to approximately 52,900 devices across its portfolio, which included approximately 46,000 devices located in 50 states of the United States, as well as in the U.S. territories of Puerto Rico and the U.S. Virgin Islands; approximately 3,500 devices throughout the United Kingdom; approximately 2,800 devices throughout Mexico; and approximately 600 devices in Canada. The company also deployed approximately 2,200 multi-function financial services kiosks in the United States. Its ATMs and financial services kiosks offer cash dispensing and bank account balance inquiry services, as well as other consumer financial services, including bill payments, check cashing, remote deposit capture, and money transfer services. In addition, the compan y provides various forms of managed service solution, including monitoring, maintenance, cash management, customer service, and transaction processing services. Further, it partners with national financial institutions to brand its ATMs and financial services kiosks with their logos. As of December 31, 2011, the company had approximately 15,400 company-owned ATMs under contract with financial institutions to place their logos on those machines. Additionally, it provides financial institutions with surcharge-free program through its Allpoint network, as well as owns and operates an electronic funds transfer transaction processing platform that provides transaction processing services to its network of ATMs and financial services kiosks, and ATMs owned and operated by third parties. The company was formerly known as Cardtronics Group, Inc. and changed its name to Cardtronics, Inc. in January 2004. Cardtronics, Inc. was founded in 1989 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Cardtronics (Nasdaq: CATM ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment